Home Mage Biologics

Mage Biologics

In operation
-
Developer of Novel Oral Monoclonal Antibodies
Basic
Enterprise Profile

Basic Information

Mage Biologics is a special purpose company aimed at developing a novel oral monoclonal antibody for the treatment of ulcerative colitis. Mage Biologics is jointly funded by TVM Life Science Innovation II and Tillotts Pharma and led by an experienced management team.
Mage Biologics, Inc.
United States of America
unclear
--
--
--

Enterprise Profile

Industrial Sector
New Drug Development
Concept
Therapeutic Products
Application Scenarios
Innovative Drugs Monoclonal Antibody